Novo’s Tresiba lowers hypoglycaemia risk compared to insulin glargine in type 2 diabetes
pharmafile | September 20, 2019 | News story | Medical Communications, Research and Development | Novo Nordisk, Tresiba, diabetes, pharma
Novo Nordisk has unveiled new data for Tresiba (insulin degludec) at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD 2019) in Barcelona, demonstrating that the drug lowered the overall risk of hypoglycaemia com with insulin glargine U300 in adults with type 2 diabetes uncontrolled on basal insulin with or without oral anti-diabetic drugs (OADs).
The results showed that the trial’s primary endpoint, the rate of overall symptomatic hypoglycaemia in the maintenance period of 36 weeks, was “numerically lower but not statistically significant”, according to Novo. However, the rate of overall symptomatic hypoglycaemia was found to be “statistically significantly lower” with Tresiba up to 88 weeks of treatment.
Novo’s drug also reduced rates of severe hypoglycaemia by 80% and of nocturnal symptomatic hypoglycaemia by 37% during the maintenance period of the study compared head-to-head to insulin glargine, and by 62% and 43% respectively in the total treatment period.
“Severe hypoglycaemia can be very worrying and potentially dangerous for people with diabetes and is important to consider as part of long-term diabetes care,” said Dr Athena Philis-Tsimikas, CONCLUDE lead investigator and Corporate Vice President at the Scripps Whittier Diabetes Institute. “The results of this trial reinforce the safety profile of Tresiba as it demonstrated a significant reduction in severe hypoglycaemia compared to insulin glargine U300 alongside effective blood glucose control.”
Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer of Novo Nordisk, also remarked: “We are delighted that the findings of the CONCLUDE trial support what we have seen previously across the Tresiba clinical development programme. These findings offer further confidence that Tresiba can help people with type 2 diabetes reduce their risk of hypoglycaemia, without having to compromise their treatment goals.”
Matt Fellows
Related Content
CHMP recommends Novo Nordisk’s Awiqli for diabetes treatment
Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for …
Roche shares data on novel solution for continuous glucose monitoring
Roche has shared the latest data on its novel solution for continuous glucose monitoring (CGM), …
Almirall licenses Novo Nordisk’s anti-IL-21 monoclonal antibody for dermatology treatment
Almirall has announced that it has entered into an exclusive license agreement with Novo Nordisk …
